Literature DB >> 31542727

The prognostic roles of and correlation between ALK and MYCN protein expression in neuroblastoma.

Hsiu-Hao Chang1, Meng-Yao Lu1, Yung-Li Yang1,2, Shu-Wei Chou1, Dong-Tsamn Lin1,2, Kai-Hsin Lin1, Wen-Ming Hsu3, Yung-Ming Jeng4,5, Shiann-Tarng Jou6.   

Abstract

AIMS: To investigate the relations between anaplastic lymphoma kinase (ALK) and v-myc myelocytomatosis viral related oncogene neuroblastoma derived homolog (MYCN) protein expression and their prognostic roles in neuroblastoma tumours.
METHODS: Sixty-one neuroblastoma tumours obtained at diagnosis were stained with anti-MYCN and anti-ALK antibodies by immunohistochemical staining. The correlations between protein expression of MYCN, ALK and clinicopathological and biological variables of neuroblastoma tumours were analysed.
RESULTS: High expression of ALK protein could be detected in 25 (41%) and high expression of MYCN protein could be detected in 24 (39.3%) of the 61 neuroblastoma tumours, respectively. The majority of neuroblastoma tumours with evident of ALK or MYCN protein high expression exhibited undifferentiated or poorly differentiated histology (30/35, 85.7%). ALK or MYCN protein high expression in neuroblastoma tumours was associated with adverse clinical prognostic factors and ALK protein high expression was significantly associated with MYCN protein high expression. In addition, either ALK or MYCN protein high expression in neuroblastoma tumours was the independent adverse prognostic factor and also predicted worse survival outcomes for neuroblastoma patients with MYCN non-amplified status or non-high-risk Children's Oncology Group grouping.
CONCLUSIONS: Our study showed a novel coordinately prognostic role of ALK and MYCN protein expression in neuroblastoma and is the first report to demonstrate the correlation between ALK and MYCN protein expression in primary neuroblastoma tumours. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ALK; MYCN; neuroblastoma; protein expression

Year:  2019        PMID: 31542727     DOI: 10.1136/jclinpath-2019-206063

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  7 in total

1.  ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.

Authors:  Dinesh Babu Somasundaram; Sheeja Aravindan; Nandita Gupta; Zhongxin Yu; Ashley Baker; Natarajan Aravindan
Journal:  World J Pediatr       Date:  2022-02-07       Impact factor: 2.764

2.  Association of Genetic Polymorphisms and Serum Levels of IL-6 and IL-8 with the Prognosis in Children with Neuroblastoma.

Authors:  Silvia Selene Moreno-Guerrero; Arturo Ramírez-Pacheco; Luz María Rocha-Ramírez; Gabriela Hernández-Pliego; Pilar Eguía-Aguilar; María Argelia Escobar-Sánchez; Alfonso Reyes-López; Luis Enrique Juárez-Villegas; Juan José Luis Sienra-Monge
Journal:  Cancers (Basel)       Date:  2021-01-30       Impact factor: 6.639

3.  Identification of a Glycosyltransferase Signature for Predicting Prognosis and Immune Microenvironment in Neuroblastoma.

Authors:  Yongliang Sha; Lei Han; Bei Sun; Qiang Zhao
Journal:  Front Cell Dev Biol       Date:  2022-01-06

Review 4.  Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.

Authors:  Anna M Wulf; Marcela M Moreno; Chloé Paka; Alexandra Rampasekova; Karen J Liu
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

5.  C1GALT1 expression predicts a favorable prognosis and suppresses malignant phenotypes via TrkA signaling in neuroblastoma.

Authors:  Neng-Yu Lin; Syue-Ting Chen; Hsiu-Ling Chang; Meng-Yao Lu; Yung-Li Yang; Shu-Wei Chou; Dong-Tsamn Lin; Kai-Hsin Lin; Shiann-Tarng Jou; Wen-Ming Hsu; Min-Chuan Huang; Hsiu-Hao Chang
Journal:  Oncogenesis       Date:  2022-02-15       Impact factor: 6.524

6.  Adult Patient With Neuroblastoma Presenting as Acute Leukemia.

Authors:  Yu-Wei Lin; Yu-Hsin Hsu; Ming-Yuan Lee
Journal:  Cureus       Date:  2022-08-08

Review 7.  Molecular targeting therapies for neuroblastoma: Progress and challenges.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2020-11-06       Impact factor: 12.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.